公开(公告)号：US20240165119A1

公开(公告)日：2024-05-23

申请号：US18495712

申请日：2023-10-26

申请人： Gilead Sciences, Inc.

发明人： Jamie Geier Bates ,  David Gordon Clarkson Breckenridge ,  John T. Liles

IPC分类号： A61K31/519 ,  A61K31/4439 ,  A61P1/16

CPC分类号： A61K31/519 ,  A61K31/4439 ,  A61P1/16

摘要： The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ACC inhibitor in combination with an FXR agonist to a patient in need thereof.

公开(公告)号：US11980609B2

公开(公告)日：2024-05-14

申请号：US17741222

申请日：2022-05-10

申请人： Gilead Sciences, Inc.

发明人： Brian P. Bestvater ,  Joshua A. Kaplan ,  Megan E. Neubig ,  Kin S. Yang ,  Anna Zagorska

IPC分类号： A61K31/4155 ,  C07D231/40 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04

CPC分类号： A61K31/4155 ,  C07D231/40 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04

摘要： The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (TLD), or chronic kidney disease (CKD).

公开(公告)号：US20240131045A1

公开(公告)日：2024-04-25

申请号：US18243812

申请日：2023-09-08

申请人： Gilead Sciences, Inc.

发明人： Casey B. Davis ,  Rita Humeniuk ,  Abdul Naveed Shaik

IPC分类号： A61K31/706

CPC分类号： A61K31/706

摘要： The present disclosure relates to methods for treating viral infections in a patient.

公开(公告)号：US20240117017A1

公开(公告)日：2024-04-11

申请号：US18468515

申请日：2023-09-15

申请人： Gilead Sciences, Inc.

发明人： Xinan Liu ,  Azure T. Makadzange ,  Stephen R. Martin ,  Hesham Shehata ,  Evguenia Svarovskaia

IPC分类号： C07K16/10 ,  A61K9/14 ,  A61K45/06 ,  C07K16/28 ,  C12N15/10

CPC分类号： C07K16/1045 ,  A61K9/14 ,  A61K45/06 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/1082

摘要： Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.

公开(公告)号：US11944611B2

公开(公告)日：2024-04-02

申请号：US16512166

申请日：2019-07-15

申请人： Gilead Sciences, Inc.

发明人： Laura Elizabeth Bauer ,  Anna Chiu ,  Eric M. Gorman ,  Andrew Stephen Mulato ,  Martin Sunkwang Rhee ,  Charles William Rowe ,  Scott P. Sellers ,  Dimitrios Stefanidis ,  Winston C. Tse ,  Stephen R. Yant ,  Dana J. Levine

IPC分类号： A61K31/4439 ,  A61K9/00 ,  A61K9/48 ,  A61K31/34 ,  A61K31/4418 ,  A61K31/536 ,  A61K31/5365 ,  A61K31/685 ,  A61P31/18

CPC分类号： A61K31/4439 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/4825 ,  A61K31/34 ,  A61K31/4418 ,  A61K31/536 ,  A61K31/5365 ,  A61K31/685 ,  A61P31/18

摘要： The present disclosure relates to compounds of Formula (Ia) and (Ib):




or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.

公开(公告)号：USD1019381S1

公开(公告)日：2024-03-26

申请号：US29842573

申请日：2022-06-14

申请人： Gilead Sciences, Inc.

设计人： Benjamin Luke Kozub ,  Brian Nilstoft ,  Kevin Nguyen ,  James Paul Oberhauser ,  Roman Shumylo ,  Joseph Anthony Cordova ,  Jinhui Yun ,  William Harold Lizor, Jr. ,  Adam Hilborn ,  Jesse Arnold Fourt ,  Léo Boris Marzolf ,  Pratap Uday Ganapathy ,  Brooke Genelle Thyng ,  Caricia Catalani ,  Soizic Porhel ,  Jose Angel Meza ,  Steven M. Scally ,  Mary Cassandra Lodwick

摘要： FIG. 1 is a front perspective view of a pharmaceutical package in an open configuration;
FIG. 2 is a back perspective view thereof;
FIG. 3 is a front view thereof;
FIG. 4 is a back view thereof;
FIG. 5 is a left side view thereof;
FIG. 6 is a right side view thereof;
FIG. 7 is a top view thereof;
FIG. 8 is a bottom view thereof;
FIG. 9 is a front perspective view of the pharmaceutical package in a partially-folded configuration;
FIG. 10 is a back perspective view thereof;
FIG. 11 is a front view thereof;
FIG. 12 is a back view thereof;
FIG. 13 is a left side view thereof;
FIG. 14 is a right side view thereof;
FIG. 15 is a top view thereof;
FIG. 16 is a bottom view thereof;
FIG. 17 is a front perspective view of the pharmaceutical package in a folded configuration;
FIG. 18 is a back perspective view thereof;
FIG. 19 is a front view thereof;
FIG. 20 is a back view thereof;
FIG. 21 is a left side view thereof;
FIG. 22 is a right side view thereof;
FIG. 23 is a top view thereof; and,
FIG. 24 is a bottom view thereof.
The broken lines, the areas within them, and the unshaded areas bounded by both broken lines and solid lines depict portions of the pharmaceutical package that form no part of the claimed design.

公开(公告)号：US11932634B2

公开(公告)日：2024-03-19

申请号：US17845469

申请日：2022-06-21

申请人： Gilead Sciences, Inc.

发明人： Michael Graupe ,  Juan A. Guerrero ,  Stephen D. Holmbo ,  Jesse M. Jacobsen ,  Tetsuya Kobayashi ,  Leena B. Patel ,  Heath A. Weaver ,  Jie Xu ,  Suet C. Yeung

IPC分类号： C07D413/14 ,  C07D239/95 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/04 ,  C07D417/12 ,  C07D471/04

CPC分类号： C07D413/14 ,  C07D239/95 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/04 ,  C07D417/12 ,  C07D471/04 ,  C07B2200/05

摘要： The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

公开(公告)号：US20240043466A1

公开(公告)日：2024-02-08

申请号：US18215881

申请日：2023-06-29

申请人： Gilead Sciences, Inc.

发明人： Kassibla E. Dempah ,  Chiajen Lai

IPC分类号： C07H17/02 ,  C07H1/06

CPC分类号： C07H17/02 ,  C07H1/06 ,  C07B2200/13

摘要： The present disclosure relates to solid forms (e.g. crystalline forms, solvates, and crystalline forms thereof) of a compound which is ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl neopentyl carbonate, which is useful in the treatment of treating viral infections, for example paramyxoviridae, pneumoviridae, picornaviridae, flaviviridae, filoviridae, arenaviridae, orthomyxovirus, and coronaviridae infections.

公开(公告)号：US20240024341A1

公开(公告)日：2024-01-25

申请号：US18202751

申请日：2023-05-26

申请人： Gilead Sciences, Inc.

发明人： Scott Ellis ,  Davin S. Rautiola ,  Dustin S. Siegel ,  Maria M. Toteva ,  Adelle A. Vandersteen

IPC分类号： A61K31/685 ,  A61P31/14 ,  A61K9/00 ,  A61K9/19 ,  A61K31/675 ,  A61K47/40

CPC分类号： A61K31/685 ,  A61P31/14 ,  A61K9/0019 ,  A61K9/0078 ,  A61K9/19 ,  A61K31/675 ,  A61K47/40

摘要： The present disclosure provides pharmaceutical formulations of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, and an aqueous vehicle. The pharmaceutical formulations of the disclosure are useful in treatment and prevention of viral infections in subjects in need thereof and are for administration by inhalation.

公开(公告)号：US11878965B2

公开(公告)日：2024-01-23

申请号：US17557860

申请日：2021-12-21

申请人： Gilead Sciences, Inc.

发明人： Daniel H. Byun ,  Zhenhong R. Cai ,  Eda Y. Canales ,  Laurent P. Debien ,  Timothy R. Hansen ,  Richard Huang ,  Petr Jansa ,  Rick A. Lee ,  Jennifer A. Loyer-Drew ,  Ryan McFadden ,  Michael L. Mitchell ,  Hyung-Jung Pyun ,  Roland D. Saito ,  Michael S. Sangi ,  Adam J. Schrier ,  Marina E. Shatskikh ,  James G. Taylor ,  Joshua J. Van Veldhuizen ,  Lianhong Xu

IPC分类号： C07D401/04 ,  A61K31/437 ,  A61K31/454 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5383 ,  A61K45/06 ,  C07D401/14 ,  C07D519/00

CPC分类号： C07D401/04 ,  A61K31/437 ,  A61K31/454 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5383 ,  A61K45/06 ,  C07D401/14 ,  C07D519/00

摘要： The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.